Clinical Trials Sponsored by Spark Therapeutics

Total 7101 results

Fulcrum Therapeutics

Completed

Safety, Tolerability and Pharmacokinetics of FTX-6058

Sickle Cell Disease | Healthy Adult Subjects

United States
Aerami Therapeutics

Completed

Safety, Tolerability, & Pharmacokinetics Study of Single & Multiple Inhaled Doses of Imatinib Inhalation Solution

Pulmonary Arterial Hypertension

Australia
United Therapeutics

Terminated

An Open Label Extension Study to Evaluate Inhaled Treprostinil in Adult PH With ILD Including CPFE

Pulmonary Hypertension | Interstitial Lung Disease | Combined Pulmonary Fibrosis and Emphysema

United States, Puerto Rico
Visus Therapeutics

Completed

Safety and Efficacy Study of BRIMOCHOL™, BRIMOCHOL™ F, and Carbachol in Subjects With Emmetropic Phakic and Pseudophakic Presbyopia

Presbyopia

United States
Summit Therapeutics

Completed

To Compare Ridinilazole Versus Vancomycin Treatment for Clostridium Difficile Infection (Ri-CoDIFy 2)

Clostridioides Difficile Infection

United States, Spain, France, Canada, Belgium, Israel, Chile, Belarus, Latvia, Germany, Romania, Lithuania, Mexico, Czechia, Estonia, Georgia, Peru
ProQR Therapeutics

Active, not recruiting

Study to Evaluate the Efficacy Safety and Tolerability of Ultevursen in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene (Sirius)

Eye Diseases | Retinitis Pigmentosa | Eye Diseases, Hereditary | Vision Disorders | Retinal Disease | Eye Disorders Congenital | Usher Syndrome Type 2 | Deaf Blind

United States, Netherlands, United Kingdom, Germany
Corcept Therapeutics

Terminated

Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Participants With Presumed Nonalcoholic Steatohepatitis (NASH)

Nonalcoholic Steatohepatitis (NASH)

United States
Heron Therapeutics

Terminated

Aprepitant Injectable Emulsion in Patients With COVID-19 (GUARDS-1)

COVID-19

United States
Fate Therapeutics

Terminated

Long-term Follow-Up Study Following Treatment With Fate Therapeutics' Engineered Cellular Immunotherapy

Hematological Malignancy

United States
Sage Therapeutics

Terminated

A Study of Brexanolone for Acute Respiratory Distress Syndrome (ARDS) Due to Coronavirus Disease 2019 (COVID-19)

COVID-19 | Acute Respiratory Distress Syndrome

United States
ASCEND Therapeutics

Completed

Study of DHT-Gel to Treat the Symptoms of Low Testosterone in Men 55-80

Hypogonadism | Low Testosterone | Late Onset Hypogonadism

United States
Centrexion Therapeutics

Completed

A Phase 3 Efficacy and Safety Study of Intra-articular CNTX-4975-05 (Capsaicin) vs Placebo in Subjects With OA Knee Pain

Osteoarthritis, Knee

United States
Aprea Therapeutics

Terminated

APR-548 in Combination With Azacitidine for the Treatment of TP53 Myelodysplastic Syndromes (MDS)

Myelodysplastic Syndromes | MDS

United States
Centrexion Therapeutics

Completed

A Clinical Study to Test Efficacy and Safety of Repeat Doses of CNTX-4975-05 in Patients With Osteoarthritis Knee Pain

Osteoarthritis, Knee

United States
Akebia Therapeutics

Completed

Efficacy and Safety Study to Evaluate Vadadustat for the Correction or Maintenance Treatment of Anemia in Participants With Incident Dialysis-dependent Chronic Kidney Disease (DD-CKD)

Anemia | Dialysis-Dependent Chronic Kidney Disease

United States, Italy, Korea, Republic of, Portugal, Russian Federation, Ukraine, Poland, Argentina, Brazil, Germany, Mexico
Akebia Therapeutics

Completed

16-Week Repeat Oral Dose Study of AKB-6548 for Anemia in Participants With End Stage Renal Disease (ESRD) Requiring Chronic Hemodialysis

Anemia | End Stage Renal Disease

United States
Corcept Therapeutics

Active, not recruiting

Study of Relacorilant in Combination With Nab-Paclitaxel for Patients With Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Primary Peritoneal Carcinoma | Recurrent Ovarian Cancer

United States, Belgium, Canada, Italy, Spain
Silverback Therapeutics

Active, not recruiting

A Study of SBT6050 Alone and in Combination With PD-1 Inhibitors in Subjects With Advanced HER2 Expressing Solid Tumors

HER2 Positive Solid Tumors

United States, Korea, Republic of, Australia
Akebia Therapeutics

Completed

Study to Assess the Safety and Pharmacokinetics of AKB-6548 in Participants With Chronic Kidney Disease (CKD), Stages 3 and 4

Chronic Kidney Disease

United States
United Therapeutics

Completed

An Open-Label, Long-Term Study of Oral Treprostinil in Subjects With Pulmonary Arterial Hypertension

Pulmonary Arterial Hypertension

Korea, Republic of, United States, Australia, Austria, Taiwan, China, Israel, Canada, India, Germany, Singapore, United Kingdom, Brazil, Italy, Netherlands, Argentina, Sweden, Chile, Denmark, France, Greece, Mexico, Poland
Audentes Therapeutics

Terminated

Gene Transfer Clinical Study in Crigler-Najjar Syndrome (VALENS)

Crigler-Najjar Syndrome

Israel, United States, United Kingdom
Blade Therapeutics

Completed

Drug-Drug Interaction (DDI) Study in Healthy Volunteers

Drug Drug Interaction

Australia
Pendulum Therapeutics

Terminated

Placebo-Controlled Clinical Nutrition Study of the Metabolic Effects of Food Product WBF-0011 in Type 2 Diabetes

Type 2 Diabetes Mellitus

Ireland
Veralox Therapeutics

Completed

Phase I Study of VLX-1005 in Healthy Subjects

Safety and Tolerability in Healthy Volunteers

United States
Syndesi Therapeutics

Terminated

A Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of SDI-118 in Elderly Male and Female Study Participants With Cognitive Decline

Cognitive Decline

United Kingdom, Germany
Elevar Therapeutics

Completed

A Study Comparing Four Different Rivoceranib Tablets in Healthy Participants

Healthy

United States
PTC Therapeutics

Completed

A Study to Assess Dystrophin Levels in Participants With Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD)

Duchenne Muscular Dystrophy

United States
HiFiBiO Therapeutics

Completed

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of HFB30132A Against COVID-19 in Chinese Healthy Adults

Healthy

China
Cartesian Therapeutics

Completed

Descartes-11 Consolidation Treatment in Patients With High-Risk Multiple Myeloma Who Have Residual Disease After Induction Therapy

Myeloma Multiple

United States
HiFiBiO Therapeutics

Completed

Study to Assess the Safety, Tolerability, and Pharmacokinetics of HFB30132A Against COVID-19 in Healthy Adults

Healthy

United States
Heron Therapeutics

Completed

Herniorrhaphy Study for Opioid Elimination

Analgesia

United States
CytomX Therapeutics

Completed

PROCLAIM-CX-072: A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas

Lymphoma | Solid Tumor

United States, Netherlands, Poland, Spain, Ukraine, United Kingdom
Corcept Therapeutics

Completed

A 4-week Study of Mifepristone in the Prevention of Risperidone-induced Weight Gain in Healthy Male Volunteers

Healthy

India
Sage Therapeutics

Completed

A Study to Evaluate SAGE-547 in Participants With Severe Postpartum Depression

Severe Postpartum Depression

United States
Allergy Therapeutics

Completed

An Exploratory Study of PQ Grass 27600 SU

Rhinitis, Allergic, Seasonal

United States, Germany
PTC Therapeutics

Completed

A Study of CNSA-001 in Women With Diabetic Gastroparesis

Gastroparesis

United States
Cadent Therapeutics

Completed

Study of CAD-9303 in Subjects With Schizophrenia (Affinity-1)

Schizophrenia

United States
Tarveda Therapeutics

Completed

PEN-221 in Somatostatin Receptor 2 Expressing Advanced Cancers Including Neuroendocrine and Small Cell Lung Cancers

Neuroendocrine Tumors | Neuroendocrine Carcinoma | Carcinoma, Small Cell Lung

United States, United Kingdom
Aptevo Therapeutics

Withdrawn

Study of APVO436 in Elderly or Unfit Patients With Newly Diagnosed AML

AML
Amicus Therapeutics

Completed

Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged 12 to <18 Years)

Fabry Disease

United Kingdom, United States
Alaunos Therapeutics

Terminated

A Study of Ad-RTS-hIL-12 + Veledimex in Pediatric Subjects With Brain Tumors Including DIPG

Diffuse Intrinsic Pontine Glioma | Pediatric Brain Tumor

United States
TR Therapeutics

Completed

Efficacy Study of GLYC-101 to Evaluate Outcomes After Laser Ablation

Wounds

United States
Heron Therapeutics

Completed

Total Knee Arthroplasty Infiltration Study for Postoperative Analgesia

Postoperative Pain

United States
Alaunos Therapeutics

Completed

A Study of Ad-RTS-hIL-12 With Veledimex in Combination With Nivolumab in Subjects With Glioblastoma; a Substudy to ATI001-102

Glioblastoma

United States
Alaunos Therapeutics

Completed

Evaluation of Ad-RTS-hIL-12 + Veledimex in Subjects With Recurrent or Progressive Glioblastoma, a Substudy to ATI001-102

Glioblastoma

United States
Alaunos Therapeutics

Completed

A Study of Ad-RTS-hIL-12 With Veledimex in Subjects With Glioblastoma or Malignant Glioma

Glioblastoma Multiforme | Anaplastic Oligoastrocytoma

United States
RANI Therapeutics

Completed

Pill Swallow Study

Not Determined

United States
Nektar Therapeutics

Completed

A Phase 2 Study To Assess The Efficacy, Tolerability, And Safety OF NKTR-181 In Subjects With Chronic OA Knee Pain

Osteoarthritis of the Knee

United States
Nektar Therapeutics

Completed

A Phase 1/2 Multicenter Dose Escalation and Expansion Study Of NKTR-214 In Subjects With Locally Advanced Or Metastatic Solid Tumors (NKTR-214)

Unspecified Adult Solid Tumor, Protocol Specific

United States
Atacama Therapeutics

Active, not recruiting

Clinical Study to Assess the Efficacy and Safety of AT-5214 in the Treatment of Subjects With Palmar Hyperhidrosis

Hyperhidrosis | Palmar Hyperhidrosis

United States

3

Subscribe